The second edition of this important book provides an up-to-date and comprehensive overview of clinical lipidology. Brand new chapters focus on recent advances in the field including novel biomarkers and the microbiome, genomics of cardiovascular risks, PCSK9 inhibitors, imaging technologies, and epidemiology of atherosclerotic cardiovascular disease.
The book describes new guidelines, novel therapeutic agents, and changes in the understanding of specific lipoproteins and subclasses with regard to their relationships to cardiovascular disease risk. The second edition contains more than thirty chapters covering such topics as the history of lipidology, lipoprotein metabolism and vascular biology, disorders of lipid metabolism, lifestyle/dietary and pharmacologic management for dyslipidemia, the management of dyslipidemia in certain subgroups (e.g., women, children, older patients) and lipid testing, as well as an examination of other biomarkers and testing procedures related toatherosclerosis and cardiovascular disease.
The second edition ofTherapeutic Lipidology is an essential resource for physicians, medical students, residents, fellows, and allied health professionals in lipidology, cardiology, endocrinology, pharmacotherapy, and health promotion and disease prevention.
Michael H. Davidson, MDProfessor, Director of the Lipid ClinicThe University of Chicago Pritzker School of Medicinemdavidso@bsd.uchicago.edu Peter P. Toth, MD, PhDDirector of Preventative Cardiology, CGH Medical CenterProfessor of Clinical Family and Community Medicine, University of Illinois College of MedicineProfessor of Clinical Medicine, Michigan State University College of Osteopathic MedicineAdjunct Associate Professor of Medicine, Johns Hopkins University School of Medicinepeter.toth@cghmc.com Kevin C. Maki, PhDPresident and Chief ScientistMidwest Biomedical Research: Center for Metabolic& Cardiovascular Healthkmaki@mbclinicalresearch.com
